Syntekabio Adopts GKE Hybrid Cloud for AI Drug Discovery

Syntekabio, an AI drug discovery company, said it has migrated from its existing AWS EKS setup to a hybrid cloud environment based on Google Cloud’s Google Kubernetes Engine(GKE) to support global expansion and modernize its infrastructure.

The transition is designed to handle rapidly growing AI research demand and strengthen the technical foundation for scaling its global drug discovery business.

Syntekabio operates proprietary AI platforms for hit and lead identification and optimization, including DeepMatcher®, NEO-ARS®, and AB-ARS®. The company aims to shorten discovery timelines often five years or more and improve efficiency and success rates in drug development with AI.

With this migration, Syntekabio has integrated its in-house AI Bio Supercomputing(ABS) Center with Google Cloud GPUs and GKE, establishing a hybrid cloud architecture.

GKE, Google Cloud’s fully managed Kubernetes service, automates large-scale container workloads and provides a standardized environment for fast, consistent deployment of AI applications. This enables Syntekabio to run complex AI workloads reliably and at scale.

Working with Google Cloud, Syntekabio completed a proof of concept(PoC) to optimize GPU-based large-scale model training and candidate analysis workloads, building an infrastructure capable of efficiently supporting the high-performance computing needs of global drug discovery projects. Robust data encryption and security features on Google Cloud are expected to help meet stringent requirements from multinational pharma companies and research institutions.

The company views the build-out as more than an infrastructure update; it marks an inflection point for commercializing AI-driven drug discovery and accelerating entry into global markets through collaborations with international partners.

Jong-Seon Jeong, CEO of Syntekabio, said, “This GKE-based cloud transition lays the technical groundwork for global expansion and further boosts our competitiveness in AI drug discovery. By combining Google Cloud’s innovative infrastructure with Syntekabio’s AI capabilities, we intend to deliver meaningful results in global markets.”

Kisung Ji, Country Director of Google Cloud Korea, said, “Syntekabio has demonstrated technological competitiveness in Korea’s AI drug discovery field, and Google Cloud will continue to support the company’s global business growth with powerful AI infrastructure and cloud technologies.”

SOURCE : https://pharm.edaily.co.kr/News/Read?newsId=02414086642363096&mediaCodeNo=257